Astrazeneca PLC (AZN): Price and Financial Metrics

Astrazeneca PLC (AZN)

Today's Latest Price: $53.50 USD

1.03 (1.96%)

Updated May 28 6:30pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • With a market capitalization of $136,526,940,000, Astrazeneca Plc has a greater market value than 98.96% of US stocks.
  • With a price/earnings ratio of 111.27, Astrazeneca Plc P/E ratio is greater than that of about 94.6% of stocks in our set with positive earnings.
  • In terms of volatility of its share price, AZN is more volatile than only 3.9% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are AMGN, LLY, SAP, BMY, and TMO.
  • Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to
AZN Daily Price Range
AZN 52-Week Price Range

AZN Stock Price Chart More Charts

AZN Price/Volume Stats

Current price $53.50 52-week high $57.44
Prev. close $52.47 52-week low $36.15
Day low $53.42 Volume 4,474,832
Day high $54.04 Avg. volume 4,382,360
50-day MA $48.80 Dividend yield 3.54%
200-day MA $47.35 Market Cap 140.40B

Astrazeneca PLC (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Astrazeneca Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:

  • The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.12%; that's greater than merely 15.14% of US stocks we're applying DCF forecasting to.
  • Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 63.79% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See PRGO, CPIX, PBYI, NRC, and RMD.

AZN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Which traditionally defensive stocks proved their worth during the coronavirus crash?

Household names Tesco, National Grid and AstraZeneca have proven their worth and their reputation as 'defensive' stocks over recent months, as global markets were rocked by coronavirus.

Daily Mail Online | May 26, 2020

The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

Zacks Investment Research | May 26, 2020

Drug company claims virus vaccine ‘will be ready in September’

British people will be able to access a coronavirus vaccine from September, the chief executive of drug-maker AstraZeneca has said, despite concerns it will not be ready.

The Scotsman | May 25, 2020

Research Report with COVID-19 Forecasts - Post-traumatic Stress Disorder Therapeutics Market 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Repor...

Benzinga Feeds | May 25, 2020

Results of Astrazeneca's Covid-19 vaccine trial due 'within weeks'

The drugs group has teamed up with scientists from Oxford University, who are developing the potential shot, and on Thursday last week it was handed a £1bn boost from the US government.

Daily Mail Online | May 25, 2020

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 4.96%
3-mo 22.15%
6-mo 12.56%
1-year 46.87%
3-year 75.64%
5-year 92.49%
YTD 9.44%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0843 seconds.